IER5L and neoplasm: The promoter methylation levels of FJX1, KLHL35, and IER5L were higher in TP53 and non-TP53-mutated tumor tissues than in normal tissues, and the methylation levels of FJX1 in non-TP53-mutated tumors were higher than those in TP53-mutated tumors.